SYNTHESIS AND MECHNISM OF DNA-CROSSLINKING OF FR900482

FR900482的合成及DNA交联机制

• 批准号: 3196583
• 负责人: Robert Michael Williams
• 金额: $ 12.72万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-04-01 至 1996-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3196583
• 关键词: DNA damage; analog; antineoplastic antibiotics; chemical structure function; crosslink; drug design /synthesis /production; mitomycin C

The objective of this program is to synthesize and study the mechanism of action of the recently discovered anti-tumor antibiotic FR-900482. This substance is a natural product isolated from the fermentation extracts of Streptomyces sandaensis No. 6897 at Fujisawa Pharmaceutical Co. in Japan. FR-900482 and its derived triacetate FK973 display potent cytotoxic and anti-tumor activity against murine and human tumors in vitro and in vivo. Structurally related to the well-known mitomycin C anti-tumor antibiotic, these new compounds are exciting due to their unique, demonstrated ability to cross-link double-stranded DNA and also form DNA-protein cross-links. Unlike mitomycin C and most other antitumor drugs, FK 973 does not cause oxidative damage to DNA. FK 973, now in advanced clinical trials in Japan, is significantly less toxic than mitomycin C and is three-fold more potent. The purpose of this investigation is to synthesize FR-900482 and some simple analogs to probe the unique mechanism of DNA-DNA and DNA-protein cross-link formation by this important new drug.

本项目的目标是合成和研究 最近发现的抗肿瘤抗生素FR-900482。 这 物质是从发酵提取物中分离的天然产物， 日本Fujisawa Pharmaceutical Co.的Streptomyces sandaensis No.6897。 FR-900482及其衍生的三乙酸FK 973显示出强效细胞毒性， 在体外和体内对鼠和人肿瘤的抗肿瘤活性。 在结构上与众所周知的丝裂霉素C抗肿瘤抗生素相关， 这些新的化合物是令人兴奋的，因为它们独特的， 使双链DNA交联并形成DNA-蛋白质交联。 与丝裂霉素C和大多数其他抗肿瘤药物不同，FK 973不会引起 氧化损伤DNA。 FK 973目前在日本进行高级临床试验， 比丝裂霉素C毒性低得多，效力高三倍。 本研究的目的是合成FR-900482和一些 简单的类似物来探测DNA-DNA和DNA-蛋白质的独特机制 这一重要新药的交联形成。